



(11) **EP 2 788 760 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention of the grant of the patent:
15.02.2017 Bulletin 2017/07

(21) Application number: **12855209.8**

(22) Date of filing: **03.12.2012**

(51) Int Cl.:
G01N 33/53 (2006.01) **C07K 14/415** (2006.01)
C12N 15/62 (2006.01) **C12N 9/10** (2006.01)
C12N 15/54 (2006.01) **G01N 33/564** (2006.01)
G01N 33/68 (2006.01)

(86) International application number:
PCT/US2012/067639

(87) International publication number:
WO 2013/085851 (13.06.2013 Gazette 2013/24)

(54) **RECOMBINANT DEAMIDATED GLIADIN ANTIGEN**

REKOMBINANTES DESAMIDIERTES GLIADIN-ANTIGEN
ANTIGÈNE DE TYPE GLIADINE DÉSAMIDÉE RECOMBINÉE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: **05.12.2011 US 201161567060 P**

(43) Date of publication of application:
15.10.2014 Bulletin 2014/42

(60) Divisional application:
16205467.0

(73) Proprietor: **Bio-rad Laboratories, Inc. Hercules, CA 94547 (US)**

(72) Inventors:
• **WALKER, Roger Benicia California 94510 (US)**
• **LU, Yabin Pleasanton California 94588 (US)**
• **DESAI, Urvee San Ramon California 94582 (US)**
• **SHAN, Daming Shoreline Washington 98133 (US)**

(74) Representative: **dompatent von Kreisler Selting Werner - Partnerschaft von Patent- und Rechtsanwälten mbB Deichmannhaus am Dom Bahnhofsvorplatz 1 50667 Köln (DE)**

(56) References cited:
WO-A2-2004/045392 WO-A2-2008/145084
WO-A2-2009/131909 US-A1- 2009 156 490
US-A1- 2009 176 251 US-A1- 2009 311 727

- **MOTHES THOMAS: "Deamidated gliadin peptides as targets for celiac disease-specific antibodies", ADVANCES IN CLINICAL CHEMISTRY, ACADEMIC PRESS, LONDON, GB, vol. 44, 1 January 2007 (2007-01-01), pages 35-63, XP009108488, ISSN: 0065-2423, DOI: 10.1016/S0065-2423(07)44002-1**
- **ALEANZI M ET AL: "Celiac disease: antibody recognition against native and selectively deamidated gliadin peptides", CLINICAL CHEMISTRY, AMERICAN ASSOCIATION FOR CLINICAL CHEMISTRY, WASHINGTON, DC, vol. 47, no. 11, 1 November 2001 (2001-11-01), pages 2023-2028, XP002666192, ISSN: 0009-9147**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 788 760 B1

- **KASPERKIEWICZ M ET AL:** "Novel assay for detecting celiac disease-associated autoantibodies in dermatitis herpetiformis using deamidated gliadin-analogous fusion peptides", **JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY** 2012 MOSBY INC. USA, vol. 66, no. 4, 16 August 2011 (2011-08-16), pages 583-588, XP002740494, ISSN: 0190-9622
- **PRAUSE CHRISTIAN ET AL:** "New Developments in Serodiagnosis of Childhood Celiac Disease Assay of Antibodies against Deamidated Gliadin", **CONTEMPORARY CHALLENGES IN AUTOIMMUNITY BLACKWELL PUBLISHING**, 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXEN, UK SERIES : **ANNALS OF THE NEW YORK ACADEMY OF SCIENCES** (ISSN 0077-8923(PRINT)), 2009, pages 28-35, XP002740495, & 6TH INTERNATIONAL CONGRESS ON AUTOIMMUNITY; OPORTO, PORTUGAL; SEPTEMBER 10 -14, 2008
- **DIETERICH ET AL.:** 'Cross linking to tissue transglutaminase and collagen favours gliadin toxicity in coeliac disease' **GUT** vol. 55, no. 4, April 2006, pages 478 - 484, XP055151395
- **DIETERICH ET AL.:** 'Cross linking to tissue transglutaminase and collagen favours gliadin toxicity in coeliac disease' **GUT** vol. 55, no. 4, April 2006, pages 478 - 484, XP055151395 Retrieved from the Internet:
<URL:<http://www.ncbi.nlm.nih.gov/pubmed/16188922>> [retrieved on 2013-02-21]

Description

BACKGROUND OF THE INVENTION

5 [0001] Celiac disease (CD) is a severe gastrointestinal disease that has a strong genetic component. CD is characterized by a permanent intolerance of proteins from wheat, barley, rye, and oats. Although the physiopathology of CD is not completely understood it is clear that the presence of the toxic proteins in the patient's diet causes a total or partial damage of intestinal mucosa (Brandtzaeg, P. 1997. Mechanisms of gastrointestinal reactions to food. Environmental Toxicology and Pharmacology 4;9-24) leading to severe malabsorption syndromes and causing diarrhea, vomiting, abdominal pain, anorexia, retarded growth, malnutrition and anemia. CD has been associated with a higher risk for intestinal cancer in non-diagnosed and untreated patients (Holmes GKT, 1989. Malignancy in coeliac disease-effect of a gluten-free diet, Gut 30;333-338). CD affects mainly children under three years old, but it is also common in adults, and sometimes is clinically atypical or asymptomatic (Ferguson A, et al. 1992. Definitions and diagnostic criteria of latent and potential coeliac disease. Ed by Auricchio S, Visakorpi J K, in Epidemiology of CD. Dyn Nutr Res, Basel, Karger 2; 119-127). CD is more frequent in patients with other genetic or autoimmune disease, such as insulin dependent diabetes mellitus, Down syndrome, selective IgA deficiency, and dermatitis herpetiformis (Sirgus N et al. 1993. Prevalence of coeliac disease in diabetic children and adolescents in Sweden. Acta Paediatr 66;491-494; Zubillaga P et al. 1993. Down syndrome and coeliac disease. J Paediatr Gastroenterol Nutr 16;168-171; Boyce N 1997).

10 [0002] The clinical symptoms of CD could be confused with those produced by other gastrointestinal diseases. In these cases CD is misdiagnosed and patients do not receive the specific treatment, that is, a complete elimination of gluten in their diet. On the other hand, if a non-celiac patient is wrongly diagnosed as celiac, he would undergo an unnecessary gluten free diet for his whole life. Accordingly, a precise diagnosis of CD is essential. Currently the standard for CD diagnosis is intestinal biopsy, repeated three times: at the onset of the clinical symptoms, after several months on a gluten free diet, and after a challenge with gluten.

15 [0003] Because intestinal biopsy is an invasive method and precise serological tests have been developed, the above criteria have been revised (Walker-Smith et al. 1990. Revised criteria for diagnosis of coeliac disease. Report of Working group of European Society of Pediatric Gastroenterology and Nutrition. Arch Dis Child 65:909-911). Currently, serological tests can be done at the onset of clinical symptoms and when they are positive, a confirmatory intestinal biopsy will be indicated. The response to the treatment with a gluten-free diet can also be followed by serological tests. If discrepancies occur between the clinical response to the treatment and the result of serological tests a second intestinal biopsy would be indicated. Several serological tests have been developed for celiac disease diagnosis, such as the detection of antibodies to cellular antigens, or antibodies to food antigens, like gliadins. There are diagnostic kits for the detection of anti-endomysial antibodies, anti-reticulin antibodies, anti-gliadin antibodies, and anti-tissue transglutaminase antibodies.

20 [0004] Anti-gliadin antibodies (AGA) have been extensively used for serological diagnosis of CD (Stern M et al. 1996. Validation and standardization of serological screening tests for coeliac disease in 1996. 3rd EMRC/ESPGAN Workshop, Dec 5-8, 1996, Molsheim, France, pp:9-24; Catassi C et al. 1999. Quantitative antigliadin antibody measurement in clinical practice: an Italian multicenter study. Ital J Gastroenterol Hepatol 31; 366-370). AGA are mainly detected by ELISA (Enzyme-Linked Immunosorbent Assay), a simpler, more objective method than IFA (indirect immunofluorescent antibody analysis), and can be used for the analysis of a large number of samples. Nevertheless AGA are less specific for CD than endomysal antibodies (EMA) and the detection of antibodies to either IgA or IgG isotypes requires two independent assays. Recently a visual immunoassay for the detection of AGA, which solves some of these problems, has been reported (Garrote J A, Sorell L, Alfonso P et al 1999. A simple visual immunoassay for the screening of coeliac disease. Eur. J Clin Invest 29; 697-699; Spanish Office for Patents and Marks No. 9801067).

25 [0005] In 1997, Dietrich *et al.* identified tissue transglutaminase (tTG), an 85 kDa protein, as the major auto antigen detected by anti-endomysial antibodies (Dietrich W et al. 1997. Identification of tissue transglutaminase as the auto antigen of celiac disease. Nat Med. 3:797-801). Detection of anti-tTG antibodies had been reported lately in ELISA or radioligand (RLA) formats based on tTG from guinea pig liver extracts or recombinant human tTG cloned from different tissues (Sulkanen S et al. 1998. Tissue transglutaminase autoantibody enzyme-linked immunosorbent assay in detecting celiac disease. Gastroenterology 115:1322-1328; Siessler J et al. 1999. Antibodies to human recombinant tissue transglutaminase measured by radioligand assay: Evidence for high diagnostic sensitivity for celiac disease. Horm Metab Res 31; 375-379).

30 [0006] Prior art methods for detection of celiac disease use specific gliadin epitopes or pieces of the gliadin protein in an assay, that lead to both false-negatives and false-positives. What is needed is an assay that provides new antigens containing a more inclusive set of epitopes that provides a more accurate assay for celiac disease. Surprisingly, the present invention meets this and other needs.

SUMMARY OF THE INVENTION

[0007] In one embodiment, the present invention provides an antigen for detecting celiac disease. The antigen includes a recombinant deamidated gliadin having a hexamer of peptides each having SEQ ID NO: 1, wherein the recombinant deamidated gliadin is covalently linked to a tag to form a gliadin fusion protein, wherein the gliadin fusion protein is immobilized on a solid support, and wherein the recombinant deamidated gliadin is capable of binding to anti-deamidated gliadin antibodies.

[0008] In other embodiments, the present invention provides an antigen for detecting celiac disease prepared by the process including contacting a solid support with a gliadin fusion protein, wherein the gliadin fusion protein includes a recombinant deamidated gliadin having a hexamer of peptides each having SEQ ID NO:1 and wherein the recombinant deamidated gliadin is covalently linked to a tag, such that the gliadin fusion protein is immobilized on the solid support. Thus, the antigen for detecting celiac disease is prepared.

[0009] In some other embodiments, the present invention provides a method for diagnosing celiac disease in a subject. The method includes contacting a sample of bodily fluid from the subject with an antigen of the present invention, including a recombinant deamidated gliadin comprising a hexamer of SEQ ID NO:3. The method also includes detecting any antibody that has become specifically bound to the antigen, thus indicating the presence of celiac disease in the subject.

[0010] In another embodiment, the present invention provides a kit including an antigen of the present invention, wherein the recombinant deamidated gliadin includes a hexamer of SEQ ID NO:3, a detection reagent, and optionally at least one of buffers, salts, stabilizers and instructions.

BRIEF DESCRIPTION OF THE DRAWINGS

[0011]

Figure 1 shows purification of D2-hexamer.

Figure 2 shows coating titration of a DGP hexamer: Calibrator Cutoff signal relative fluorescence intensity (RFI).

Figure 3 shows coating titration of a DGP hexamer with a lysine substituted for the glutamic acid residue at position 14: Calibrator Cutoff signal RFI.

Figure 4 shows the rDGP hexamer has improved sensitivity as compared to the rDGP trimer.

DETAILED DESCRIPTION OF THE INVENTION

I. Definitions

[0012] As used herein, the term "contacting" refers to the process of bringing into contact at least two distinct species such that they can react. The resulting reaction product is either produced directly from a reaction between the added reagents or from an intermediate from one or more of the added reagents which can be produced in the reaction mixture.

[0013] As used herein, the term "bodily fluid" refers to fluids of a mammal including, but not limited to, aqueous humour, bile, blood and blood plasma, breast milk, interstitial fluid, lymph, mucus, pleural fluid, pus, saliva, serum, sweat, tears, urine, cerebrospinal fluid, synovial fluid or intracellular fluid. One of skill in the art will appreciate that other bodily fluids are useful in the present invention.

[0014] As used herein, the term "cross-linker" refers to a bifunctional or multi-functional chemical or biological moiety that is capable of linking two separate moieties together. Examples of cross-linkers useful in the present invention are described below.

[0015] As used herein, "antibody" includes reference to an immunoglobulin molecule immunologically reactive with a particular antigen, and includes both polyclonal and monoclonal antibodies.

[0016] As used herein, the term "subject" refers to animals such as mammals, including, but not limited to, primates (e.g., humans), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice and the like.

[0017] As used herein, the term "immobilized" refers to the association of the tTG, the gliadin fusion protein or the tTG-gliadin fusion protein complex with a solid support material through covalent bond formation, ionic bond formation, hydrogen-bonding, dipole-dipole interaction or via Van der Waals interactions. The immobilization can be temporary or permanent.

[0018] As used herein, the term "antigen" refers to a molecule that is capable of stimulating an immune response such as by production of antibodies. Antigens of the present invention include solid support immobilized gliadin fusion protein and solid support immobilized tTG-gliadin fusion protein complex. The gliadin fusion protein of the present invention can

include both a recombinant deamidated gliadin and a tag, such as Glutathione S-transferase (GST) protein.

[0019] As used herein, the term "buffers" refers to any inorganic or organic acid or base that resists changes in pH and maintains the pH around a desired point. Buffering agents useful in the present invention include, but are not limited to, sodium hydroxide, dibasic sodium phosphate anhydrous, and mixtures thereof. One of skill in the art will appreciate that other buffering agents are useful in the present invention.

[0020] As used herein, the term "tissue Transglutaminase (tTG)" refers to an enzyme of the transglutaminase family that crosslinks proteins between an amino group of a lysine residue and a carboxamide group of a glutamine residue. This creates an intermolecular or intramolecular bond. tTG can be used to detect celiac disease.

[0021] As used herein, the term "gliadin fusion protein" refers to a gliadin protein linked to a tag, such as Glutathione S-transferase (GST) or a His tag. The gliadin protein includes a recombinant gliadin protein or a synthetic gliadin protein, among others. In some embodiments, the gliadin protein is deamidated. Tags are typically other proteins or compounds that can be used as affinity tags for purification, for solubilization, chromatography, as epitope tags, fluorescence tags, and others. Tags useful in the present invention include, but are not limited to, BCCP, c-myc-tag, Calmodulin-tag, FLAG-tag, HA-tag, His-tag, Maltose binding protein-tag, Nus-tag, Glutathione-S-transferase (GST) tag, Green fluorescent protein-tag, Thioredoxin-tag, S-tag, Streptag II, Softag 1, Softag 3, T7-tag, Elastin-like peptides, Chitin-binding domain, and Xylanase 10A. One of skill in the art will appreciate that other proteins are useful in fusion proteins of the present invention.

[0022] As used herein, the term "tTG-gliadin fusion protein complex" refers to a complex formed when the tTG and the gliadin fusion protein become linked together. The tTG and the gliadin fusion protein can be linked in a variety of ways, under a variety of reactions. The tTG can be linked to either or both of the tag and the recombinant deamidated gliadin of the gliadin fusion protein.

[0023] As used herein, the term "recombinant deamidated gliadin" refers to a deamidated gliadin protein prepared via genetic engineering. Deamidated proteins are those that have had some or all of the free amide functional groups hydrolyzed to carboxylic acids, such as conversion of glutamines to glutamic acid. In some embodiments, recombinant deamidated gliadins useful in the present invention comprise peptides having at least 75% sequence identity to SEQ ID NO:1 or comprise a hexamer having at least 75% sequence identity to SEQ ID NO:3.

[0024] As used herein, the term "crosslinked" refers to the formation of more than one bond between two different chemical moieties. In the present invention, the chemical moieties can be biological species such as proteins, enzymes, antibodies, etc., or solid support materials. The chemical functionality that links the individual chemical moieties that are crosslinked, is termed a "crosslinker". A crosslinker is typically a bifunctional compound that reacts with one reactive functional group on one chemical moiety and one reactive functional group on another chemical moiety, thereby linking the two chemical moieties to each other. The crosslinkers can be homobifunctional crosslinkers or heterobifunctional crosslinkers. Homobifunctional crosslinkers are those where the functional groups of the homobifunctional crosslinker that react with each chemical moiety are the same. Heterobifunctional crosslinkers are those where the functional groups of the heterobifunctional crosslinker that react with each chemical moiety are different. Preferred homobifunctional and heterobifunctional crosslinkers of the present invention are described in greater detail below.

[0025] As used herein, the terms "identical" or percent "identity," in the context of two or more nucleic acids or polypeptide sequences, refer to two or more sequences or subsequences that are the same or have a specified percentage of amino acid residues or nucleotides that are the same (*i.e.*, 60% identity, preferably 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity over a specified region), when compared and aligned for maximum correspondence over a comparison window, or designated region as measured using one of the following sequence comparison algorithms or by manual alignment and visual inspection. This definition also refers to the complement of a test sequence.

[0026] The phrase "substantially identical," in the context of two nucleic acids or polypeptides, refers to a sequence or subsequence that has at least 40% sequence identity with a reference sequence. Alternatively, percent identity can be any integer from 40% to 100%. More preferred embodiments include at least: 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% compared to a reference sequence using the programs described herein; preferably BLAST using standard parameters, as described below.

[0027] For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters. For sequence comparison of nucleic acids and proteins, the BLAST and BLAST 2.0 algorithms and the default parameters discussed below are used.

[0028] Preferred examples of algorithms that are suitable for determining percent sequence identity and sequence similarity are the BLAST and BLAST 2.0 algorithms, which are described in Altschul et al., *Nuc. Acids Res.* 25:3389-3402

(1977) and Altschul et al., J. Mol. Biol. 215:403-410 (1990), respectively. BLAST and BLAST 2.0 are used, with the parameters described herein, to determine percent sequence identity for the nucleic acids and proteins of the invention. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/>). This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length *W* in the query sequence, which either match or satisfy some positive-valued threshold score *T* when aligned with a word of the same length in a database sequence. *T* is referred to as the neighborhood word score threshold (Altschul *et al.*, *supra*). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters *M* (reward score for a pair of matching residues; always > 0) and *N* (penalty score for mismatching residues; always < 0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity *X* from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters *W*, *T*, and *X* determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a word length (*W*) of 11, an expectation (*E*) of 10, *M*=5, *N*=-4 and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a word length of 3, and expectation (*E*) of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff, Proc. Natl. Acad. Sci. USA 89:10915 (1989)) alignments (*B*) of 50, expectation (*E*) of 10, *M*=5, *N*=-4, and a comparison of both strands.

[0029] The BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, *e.g.*, Karlin & Altschul, Proc. Nat'l. Acad. Sci. USA 90:5873-5787 (1993)). One measure of similarity provided by the BLAST algorithm is the smallest sum probability (*P(N)*), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a reference sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.2, more preferably less than about 0.01, and most preferably less than about 0.001.

[0030] An indication that two nucleic acid sequences or polypeptides are substantially identical is that the polypeptide encoded by the first nucleic acid is immunologically cross reactive with the antibodies raised against the polypeptide encoded by the second nucleic acid, as described below. Thus, a polypeptide is typically substantially identical to a second polypeptide, for example, where the two peptides differ only by conservative substitutions. Another indication that two nucleic acid sequences are substantially identical is that the two molecules or their complements hybridize to each other under stringent conditions. Yet another indication that two nucleic acid sequences are substantially identical is that the same primers can be used to amplify the sequence.

[0031] As used herein, the terms "nucleic acid" and "polynucleotide" are used synonymously and refer to a single or double-stranded polymer of deoxyribonucleotide or ribonucleotide bases read from the 5' to the 3' end. A nucleic acid of the present invention will generally contain phosphodiester bonds, although in some cases, nucleic acid analogs may be used that may have alternate backbones, comprising, *e.g.*, phosphoramidate, phosphorothioate, phosphorodithioate, or O-methylphosphoroamidite linkages (see Eckstein, *Oligonucleotides and Analogues: A Practical Approach*, Oxford University Press); and peptide nucleic acid backbones and linkages. Other analog nucleic acids include those with positive backbones; non-ionic backbones, and non-ribose backbones. Thus, nucleic acids or polynucleotides may also include modified nucleotides, that permit correct read through by a polymerase. "Polynucleotide sequence" or "nucleic acid sequence" includes both the sense and antisense strands of a nucleic acid as either individual single strands or in a duplex. As will be appreciated by those in the art, the depiction of a single strand also defines the sequence of the complementary strand; thus the sequences described herein also provide the complement of the sequence. Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses variants thereof (*e.g.*, degenerate codon substitutions) and complementary sequences, as well as the sequence explicitly indicated. The nucleic acid may be DNA, both genomic and cDNA, RNA or a hybrid, where the nucleic acid may contain combinations of deoxyribo- and ribo-nucleotides, and combinations of bases, including uracil, adenine, thymine, cytosine, guanine, inosine, xanthine hypoxanthine, isocytosine, isoguanine, etc.

[0032] As used herein, the phrase "a nucleic acid sequence encoding" refers to a nucleic acid which contains sequence information for a structural RNA such as rRNA, a tRNA, or the primary amino acid sequence of a specific protein or peptide, or a binding site for a transacting regulatory agent. This phrase specifically encompasses degenerate codons (*i.e.*, different codons which encode a single amino acid) of the native sequence or sequences that may be introduced to conform with codon preference in a specific host cell.

[0033] As used herein, the term "specifically bound" refers to the capturing or entrapment of the antigen of the present invention by an antibody that is indicative of the presence of celiac disease. Thus, under designated immunoassay conditions, an antibody (*e.g.*, an anti-deamidated gliadin antibody) binds an antigen of the present invention at at least two times over background level and more typically at at least 5, 10, 20, 30, 40, or 50 times over background level. A variety of immunoassay formats may be used to determine whether an antibody specifically binds an antigen of the

present invention. For example, solid-phase ELISA immunoassays are routinely used to determine whether an antibody is specifically immunoreactive with a protein (see, e.g., Harlow & Lane, *Using Antibodies, A Laboratory Manual* (1998) for a description of immunoassay formats and conditions that can be used to determine specific immunoreactivity).

5 II. Antigen


[0034] The present invention provides an antigen and method for detection of celiac disease. The antigen includes a gliadin fusion protein immobilized on a solid support material. The gliadin fusion protein includes both a recombinant deamidated gliadin and a tag. The antigen can optionally include tissue Transglutaminase (tTG). When present, the gliadin fusion protein and tTG can be covalently linked prior to immobilization on the solid support, such as via transamidation, to form a tTG-gliadin fusion protein complex. Following immobilization of the tTG-gliadin fusion protein complex on the solid support, the gliadin fusion protein and the tTG can be cross-linked using suitable cross-linkers.

[0035] In some embodiments, the present invention provides an antigen for detecting celiac disease. The antigen of the present invention includes the solid support bound gliadin fusion protein described below.

[0036] In other embodiments, the present invention provides an antigen for detecting celiac disease. The antigen includes a recombinant deamidated gliadin having a hexamer of peptides each having the sequence of SEQ ID NO: 1, wherein the recombinant deamidated gliadin is covalently linked to a tag to form a gliadin fusion protein, wherein the gliadin fusion protein is immobilized on a solid support, and wherein the recombinant deamidated gliadin is capable of binding to anti-deamidated gliadin antibodies.

20 A. Gliadin Fusion Protein

[0037] The gliadin fusion protein useful in the present invention includes a recombinant deamidated gliadin that is expressed as a tagged protein. One of skill in the art will recognize that many recombinant gliadin proteins are useful in the method of the present invention. In some embodiments, the recombinant gliadin protein can include D2 (Aleanzi et al, *Clin Chem* 2001, 47 (11), 2023), peptide sequence: QPEQPQSFPEQERPF (SEQ ID NO: 1). The recombinant gliadin protein can also include variants of D2, represented by the following formula:



wherein each X is either glutamine (Q) or glutamic acid (E) such that at least one X is glutamine and at least one X is glutamic acid. The recombinant gliadin protein of the present invention can also be a hexamer of D2 or its variants. In some embodiments, the recombinant gliadin protein is a hexamer of D2 or its variants, separated by any suitable spacer, such as GGGGS (SEQ ID NO:2). One of skill in the art will appreciate that other spacers are useful in the present invention.

[0038] Any suitable spacer is useful in the present invention, and are interchangeable with linkers. Typical peptide spacer sequences contain Gly, Ser, Ala and Thr residues. Useful spacer include glycine-serine polymers including, for example, (GGGGS)_n (SEQ ID NO:13), (GS)_n, (GSGGS)_n (SEQ ID NO:14), and (GGGS)_n (SEQ ID NO:15), where n is an integer of at least one; glycine-alanine polymers; alanine-serine polymers; and other flexible linkers.

[0039] In some embodiments, the hexamer includes a spacer separating each peptide having the sequence of SEQ ID NO:1. In other embodiments, each spacer can have the sequence of SEQ ID NO:2.

[0040] In some embodiments, the recombinant deamidated gliadin is a D2 hexamer (SEQ ID NO:3). In some other embodiments, the present invention provides any nucleotide sequence that encodes the polypeptide in the sequence of SEQ ID NO:1 or SEQ ID NO:3. The recombinant deamidated gliadin proteins of the present invention bind to anti-deamidated gliadin antibodies, and are thus able to diagnose subjects having gluten related disorders such as celiac disease. One of skill in the art will appreciate that other recombinant deamidated gliadin proteins are useful in the present invention.

[0041] The gliadin fusion protein also includes a tag. Any tag known in the art is useful in the gliadin fusion proteins of the present invention. Tags suitable in the antigen of the present invention include, but are not limited to, a Glutathione S-transferase (GST), His-tag, FLAG, Streptag II, HA-tag, Softag 1, Softag 3, c-myc, T7-tag, S-tag, Elastin-like peptides, Chitin-binding domain, thioredoxin, Xylanase 10A, Maltose binding protein and NusA. In some embodiments, the tag is a Glutathione S-transferase (GST) or a His-tag. One of skill in the art will appreciate that other tags are useful in the present invention. The tag is typically attached to the recombinant gliadin protein via covalent linkage.

[0042] The His-tag useful in the present invention can be any suitable His-tag. His-tags suitable in the present invention include, but are not limited to, the sequence of SEQ ID NO:4, SEQ ID NO:5, or SEQ ID NO:6. In some embodiments, the His-tag can be the sequence of SEQ ID NO:5 or SEQ ID NO:6. In other embodiments, the recombinant deamidated gliadin can be the sequence of SEQ ID NO:7 or SEQ ID NO:8.

[0043] In another embodiment, the tag is a Glutathione S-transferase (GST) protein. The GST protein (SEQ ID NO:10) serves many functions, including enabling the purification of the recombinant gliadin protein and the presentation of

epitopes represented in the recombinant gliadin protein.

[0044] When the gliadin fusion protein includes GST and the recombinant deamidated gliadin is the D2 hexamer, the gliadin fusion protein is represented by the sequence of SEQ ID NO: 11. In some embodiments, the present invention provides any nucleotide sequence that encodes the polypeptide in the sequence of SEQ ID NO: 11. The gliadin fusion protein of the present invention can be prepared by a variety of methods, including via recombinant methods such as those described.

[0045] Immobilization of the gliadin fusion protein on the solid support can be achieved by any method known in the art. The immobilization of the gliadin fusion protein to the solid support can be via covalent or ionic bond formation, hydrogen bonding, Van der Waals forces, as well as via antibody-antigen interactions. One of skill in the art will appreciate that other immobilization methods are useful in the present invention.

[0046] In some embodiments, the antigen also includes tissue Transglutaminase (tTG). When tTG is present, the tTG and gliadin fusion protein form a tTG-gliadin fusion protein complex. The tTG and the gliadin fusion protein can be linked in a variety of ways, such as by the formation of covalent bonds, ionic bonds, hydrogen bonding, or by Van der Waals interactions. When the tTG and the gliadin fusion protein are linked covalently, the covalent bonds can be formed by a variety of reactions, such as transamidation. The transamidation can occur under a variety of conditions, such as in the presence of Ca^{2+} . The tTG can be linked to either or both of the tag and the recombinant deamidated gliadin of the gliadin fusion protein. The tTG is immobilized to the solid support under the same conditions, and at the same time as immobilization of the gliadin fusion protein. Tissue transglutaminase is known to one of skill in the art and has been described previously, see NCBI RefSeq NP_004604 and NP_945189 (April 13, 2008).

[0047] In other embodiments, the tTG and the gliadin fusion protein are covalently linked by a cross-linker. One of skill in the art will appreciate that other methods of cross-linking are available, such as via ionic bonding, hydrogen bonding or via van der Waals forces. One of skill in the art will recognize that any cross-linker is suitable in the instant invention. In some embodiments, the cross-linker is a member selected from the group consisting of a heterobifunctional crosslinker and a homobifunctional crosslinker. In yet other embodiments, the cross-linker is a homobifunctional crosslinker. In still yet other embodiments, the cross-linker is a member selected from the group consisting of bis(sulfosuccinimidyl)suberate (BS3), ethylene glycol bis[succinimidylsuccinate] (EGS), ethylene glycol bis[sulfosuccinimidylsuccinate] (sulfo-EGS), bis[2-(succinimidooxycarbonyloxy)ethyl]sulfone (BSOCOES), dithiobis(succinimidyl)propionate (DSP), 3,3'-dithiobis(sulfosuccinimidyl)propionate (DTSSP), disuccinimidyl suberate (DSS), disuccinimidyl glutarate (DSG), methyl N-succinimidyl adipate (MSA), disuccinimidyl tartarate (DST), 1,5-difluoro-2,4-dinitrobenzene (DFDNB), 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC or EDAC), sulfosuccinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (sulfo-SMCC), N-hydroxysulfosuccinimide (sulfo-NHS), hydroxylamine and Sulfo-LC-SPDP (N-succinimidyl 3-(2-pyridyldithio)-propionate) and sulfosuccinimidyl 6-(3'-[2-pyridyldithio]-propionamido)hexanoate (sulfo-LC-SPDP). In another embodiment, the cross-linker is bis(sulfosuccinimidyl)suberate (BS3).

[0048] In a further embodiment, the recombinant deamidated gliadin has 95% identity to SEQ ID NO:3. One of skill in the art will appreciate that other percent identities are possible, such as 60% identity, preferably 65%, 70%, 75%, 80%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity over a specified region, when compared and aligned for maximum correspondence over a comparison window, or designated region. Such sequences are then said to be "substantially identical." The recombinant deamidated gliadin of the present invention having some percent identity to the sequence of SEQ ID NO:3 can bind to anti-gliadin antibodies in a sample in order to detect celiac disease. In some other embodiments, the recombinant deamidated gliadin has the sequence of SEQ ID NO:3.

B. Solid Support

[0049] A solid support material for use in the present invention is characterized by the following properties: (1) insolubility in liquid phases used for screening; (2) capable of mobility in three dimensions independent of all other supports; (3) containing many copies of the gliadin fusion protein or the tTG-gliadin fusion protein complex; (4) compatibility with screening assay conditions; and (5) being inert to the assay conditions. A preferred support also has reactive functional groups, including, but not limited to, hydroxyl, carboxyl, amino, thiol, aldehyde, halogen, nitro, cyano, amido, urea, carbonate, carbamate, isocyanate, sulfone, sulfonate, sulfonamide, sulfoxide, etc., for attaching the gliadin fusion protein and tTG.

[0050] As used herein, solid support material is not limited to a specific type of support. Rather a large number of supports are available and are known to one of ordinary skill in the art. Solid phase supports include silica gels, resins, derivatized plastic films, beads such as glass, plastic, or magnetic beads, cotton, alumina gels, polysaccharides such as Sepharose and the like, etc. Other solid supports can be ELISA microtiter plates. A suitable solid phase support can be selected on the basis of desired end use and suitability for various synthetic protocols. For example, in polyamide synthesis, useful solid phase support can be resins such as polystyrene (e.g., PAM-resin obtained from Bachem Inc., Peninsula Laboratories, etc.), POLYHIPE™ resin (obtained from Aminotech, Canada), polyamide resin (obtained from

Peninsula Laboratories), polystyrene resin grafted with polyethylene glycol (TentaGel™, Rapp Polymere, Tubingen, Germany), polydimethyl-acrylamide resin (available from Milligen/Bioscience, California), or PEGA beads (obtained from Polymer Laboratories). Preferred solid phase synthesis supports for specific syntheses are described below. In some embodiments, the solid support is a bead. One of skill in the art will recognize that many types of solid supports are useful in the present invention.

C. Process for Preparing Recombinant Deamidated Gliadin Antigen

[0051] In some embodiments, the present invention provides an antigen for detecting celiac disease prepared by the process including contacting a solid support with a gliadin fusion protein, wherein the gliadin fusion protein includes a recombinant deamidated gliadin having a hexamer of peptides each having the sequence of SEQ ID NO:1 and wherein the recombinant deamidated gliadin is covalently linked to a tag, such that the gliadin fusion protein is immobilized on the solid support. Thus, the antigen for detecting celiac disease is prepared.

[0052] The process of preparing the recombinant deamidated gliadin antigen can prepare any recombinant deamidated gliadin antigen described above.

[0053] The tag is as described above. In some embodiments, the tag is GST or a His-tag. In another embodiment, the tag is GST. In some embodiments, the gliadin fusion protein is immobilized on the solid support via the tag.

[0054] The solid support is as described above. In some embodiments, the solid support is a bead, such as a magnetic bead. In some embodiments, the solid support has a functional reactive group.

[0055] When tTG is present, the process can also include forming a covalent bond between the gliadin fusion protein and the tTG prior to the contacting step to form a tTG-gliadin fusion protein complex. The process of forming a covalent bond between the gliadin fusion protein and the tTG can also occur during and/or after the contacting step. The complexing of the gliadin fusion protein and the tTG can occur by any method known in the art. In some embodiments, the complexation occurs by transamidation to form a covalent bond.

[0056] In other embodiments, the process further comprises contacting the solid support with a cross-linker to cross-link the gliadin fusion protein and the tTG. In some other embodiments, the cross-linker cross-links the GST protein to the tTG. One of skill in the art will appreciate that any cross-linker is useful in the process of the present invention, such as those described above. The cross-linking can occur via hydrogen-bonding, covalent or ionic bond formation.

1. General Recombinant Methods

[0057] This invention can employ routine techniques in the field of recombinant genetics for the preparation of recombinant deamidated gliadin polypeptides. Basic texts disclosing the general methods of use in this invention include Sambrook & Russell, *Molecular Cloning, A Laboratory Manual* (3rd Ed, 2001); Kriegler, *Gene Transfer and Expression: A Laboratory Manual* (1990); and *Current Protocols in Molecular Biology* (Ausubel et al., eds., 1994-1999).

[0058] A recombinant deamidated gliadin, or a fusion protein, e.g., comprising recombinant deamidated gliadin and a tag such as a GST tag or a His tag, can be expressed using techniques well known in the art. Eukaryotic and prokaryotic host cells may be used such as animal cells, insect cells, bacteria, fungi, and yeasts. Methods for the use of host cells in expressing isolated nucleic acids are well known to those of skill and may be found, for example, in the general reference, *supra*. Accordingly, this invention also provides for host cells and expression vectors comprising the nucleic acid sequences described herein.

[0059] Nucleic acids encoding a recombinant deamidated gliadin, or a fusion protein, e.g., comprising recombinant deamidated gliadin and a tag such as a GST tag or a His tag, can be made using standard recombinant or synthetic techniques. Nucleic acids may be RNA, DNA, or hybrids thereof. One of skill can construct a variety of clones containing functionally equivalent nucleic acids, such as nucleic acids that encode the same polypeptide. Cloning methodologies to accomplish these ends, and sequencing methods to verify the sequence of nucleic acids are well known in the art.

[0060] In some embodiments, the nucleic acids are synthesized *in vitro*. Deoxynucleotides may be synthesized chemically according to the solid phase phosphoramidite triester method described by Beaucage & Caruthers, *Tetrahedron Letts.* 22(20):1859-1862 (1981), using an automated synthesizer, e.g., as described in Needham-VanDevanter, et al., *Nucleic Acids Res.* 12:6159-6168 (1984). In other embodiments, the nucleic acids encoding the desired protein may be obtained by an amplification reaction, e.g., PCR.

[0061] One of skill will recognize many other ways of generating alterations or variants of a given polypeptide sequence. Most commonly, polypeptide sequences are altered by changing the corresponding nucleic acid sequence and expressing the polypeptide.

[0062] One of skill can select a desired nucleic acid or polypeptide of the invention based upon the sequences referred to herein and the knowledge readily available in the art regarding recombinant deamidated gliadin structure and function. The physical characteristics and general properties of these proteins are known to skilled practitioners.

[0063] To obtain high level expression of a recombinant deamidated gliadin, or a fusion protein comprising recombinant

deamidated gliadin and a tag such as a GST tag or a His tag, an expression vector is constructed that includes such elements as a promoter to direct transcription, a transcription/translation terminator, a ribosome binding site for translational initiation, and the like. Suitable bacterial promoters are well known in the art and described, e.g., in the references providing expression cloning methods and protocols cited hereinabove. Bacterial expression systems for expressing ribonuclease are available in, e.g., *E. coli*, *Bacillus sp.*, and *Salmonella* (see, also, Palva, et al., *Gene* 22:229-235 (1983); Mosbach, et al., *Nature* 302:543-545 (1983)). Kits for such expression systems are commercially available. Eukaryotic expression systems for mammalian cells, yeast, and insect cells are well known in the art and are also commercially available.

[0064] In addition to the promoter, the expression vector typically contains a transcription unit or expression cassette that contains all the additional elements required for expression of the nucleic acid in host cells. A typical expression cassette thus contains a promoter operably linked to the nucleic acid sequence encoding the recombinant deamidated gliadin or the fusion protein (e.g., a recombinant deamidated gliadin-GST fusion protein), and signals required for efficient polyadenylation of the transcript, ribosome binding sites, and translation termination. Depending on the expression system, the nucleic acid sequence encoding the recombinant deamidated gliadin or fusion protein (e.g., recombinant deamidated gliadin-GST fusion protein) may be linked to a cleavable signal peptide sequence to promote secretion of the encoded protein by the transformed cell.

[0065] As noted above, the expression cassette should also contain a transcription termination region downstream of the structural gene to provide for efficient termination. The termination region may be obtained from the same gene as the promoter sequence or may be obtained from different genes.

[0066] The particular expression vector used to transport the genetic information into the cell is not particularly critical. Any of the conventional vectors used for expression in eukaryotic or prokaryotic cells may be used. Standard bacterial expression vectors include plasmids such as pBR322 based plasmids, pSKF, pET15b, pET23D, pET-22b(+), and fusion expression systems such as GST and LacZ. Epitope tags can also be added to recombinant proteins to provide convenient methods of isolation, e.g., 6-his. These vectors comprise, in addition to the expression cassette containing the coding sequence, the T7 promoter, transcription initiator and terminator, the pBR322 ori site, a bla coding sequence and a lac1 operator.

[0067] The vectors comprising the nucleic acid sequences encoding the RNase molecules or the fusion proteins may be expressed in a variety of host cells, including *E. coli*, other bacterial hosts, yeast, and various higher eukaryotic cells such as the COS, CHO and HeLa cells lines and myeloma cell lines. In addition to cells, vectors may be expressed by transgenic animals, preferably sheep, goats and cattle. Typically, in this expression system, the recombinant protein is expressed in the transgenic animal's milk.

[0068] The expression vectors or plasmids of the invention can be transferred into the chosen host cell by well-known methods such as calcium chloride transformation for *E. coli* and calcium phosphate treatment, liposomal fusion or electroporation for mammalian cells. Cells transformed by the plasmids can be selected by resistance to antibiotics conferred by genes contained on the plasmids, such as the amp, gpt, neo and hyg genes.

[0069] Once expressed, the expressed protein can be purified according to standard procedures of the art, including ammonium sulfate precipitation, column chromatography (including affinity chromatography), gel electrophoresis and the like (see, generally, R. Scopes, *Protein Purification*, Springer-Verlag, N.Y. (1982), Deutscher, *Methods in Enzymology* Vol. 182: *Guide to Protein Purification*, Academic Press, Inc. N.Y. (1990); Sambrook and Ausubel, both *supra*).

[0070] In some embodiments, the present invention provides an isolated nucleic acid including the sequence of SEQ ID NO:9, which encodes a recombinant gliadin protein D2 hexamer sequence. In other embodiments, the isolated nucleic acid is in an expression vector. In some other embodiments, the expression vector is in a host cell.

2. Immobilization on the Solid Support

[0071] The gliadin fusion protein of the present invention can be immobilized to any useful solid support material by any useful immobilization method known in the art. The immobilization of the gliadin fusion protein to the solid support can be via covalent or ionic bond formation, hydrogen bonding, Van der Waals forces, as well as via antibody-antigen interactions. One of skill in the art will appreciate that other immobilization methods are useful in the present invention.

[0072] Other compounds have been developed that enable immobilization in a manner similar to antibodies. Certain of these "antibody mimics" use non-immunoglobulin protein scaffolds as alternative protein frameworks for the variable regions of antibodies.

[0073] For example, Ladner et al. (U.S. Patent No. 5,260,203) describe single polypeptide chain binding molecules with binding specificity similar to that of the aggregated, but molecularly separate, light and heavy chain variable region of antibodies. The single-chain binding molecule contains the antigen binding sites of both the heavy and light variable regions of an antibody connected by a peptide linker and will fold into a structure similar to that of the two peptide antibody. The single-chain binding molecule displays several advantages over conventional antibodies, including, smaller size, greater stability and are more easily modified.

[0074] Ku et al. (Proc. Natl. Acad. Sci. U.S.A. 92(14):6552-6556 (1995)) discloses an alternative to antibodies based on cytochrome b₅₆₂. Ku et al. (1995) generated a library in which two of the loops of cytochrome b₅₆₂ were randomized and selected for binding against bovine serum albumin. The individual mutants were found to bind selectively with BSA similarly with anti-BSA antibodies.

[0075] Lipovsek et al. (U.S. Patent Nos. 6,818,418 and 7,115,396) discloses an antibody mimic featuring a fibronectin or fibronectin-like protein scaffold and at least one variable loop. Known as Adnectins, these fibronectin-based antibody mimics exhibit many of the same characteristics of natural or engineered antibodies, including high affinity and specificity for any targeted ligand. Any technique for evolving new or improved binding proteins may be used with these antibody mimics.

[0076] The structure of these fibronectin-based antibody mimics is similar to the structure of the variable region of the IgG heavy chain. Therefore, these mimics display antigen binding properties similar in nature and affinity to those of native antibodies. Further, these fibronectin-based antibody mimics exhibit certain benefits over antibodies and antibody fragments. For example, these antibody mimics do not rely on disulfide bonds for native fold stability, and are, therefore, stable under conditions which would normally break down antibodies. In addition, since the structure of these fibronectin-based antibody mimics is similar to that of the IgG heavy chain, the process for loop randomization and shuffling may be employed *in vitro* that is similar to the process of affinity maturation of antibodies *in vivo*.

[0077] Beste et al. (Proc. Natl. Acad. Sci. U.S.A. 96(5):1898-1903 (1999)) discloses an antibody mimic based on a lipocalin scaffold (ANTICALIN®). Lipocalins are composed of a β-barrel with four hypervariable loops at the terminus of the protein. Beste (1999), subjected the loops to random mutagenesis and selected for binding with, for example, fluorescein. Three variants exhibited specific binding with fluorescein, with one variant showing binding similar to that of an anti-fluorescein antibody. Further analysis revealed that all of the randomized positions are variable, indicating that ANTICALIN® would be suitable to be used as an alternative to antibodies.

[0078] ANTICALINS® are small, single chain peptides, typically between 160 and 180 residues, which provides several advantages over antibodies, including decreased cost of production, increased stability in storage and decreased immunological reaction.

[0079] Hamilton et al. (U.S. Patent No. 5,770,380) discloses a synthetic antibody mimic using the rigid, non-peptide organic scaffold of calixarene, attached with multiple variable peptide loops used as binding sites. The peptide loops all project from the same side geometrically from the calixarene, with respect to each other. Because of this geometric confirmation, all of the loops are available for binding, increasing the binding affinity to a ligand. However, in comparison to other antibody mimics, the calixarene-based antibody mimic does not consist exclusively of a peptide, and therefore it is less vulnerable to attack by protease enzymes. Neither does the scaffold consist purely of a peptide, DNA or RNA, meaning this antibody mimic is relatively stable in extreme environmental conditions and has a long life span. Further, since the calixarene-based antibody mimic is relatively small, it is less likely to produce an immunogenic response.

[0080] Murali et al. (Cell Mol Biol 49(2):209-216 (2003)) discusses a methodology for reducing antibodies into smaller peptidomimetics, which they term "antibody like binding peptidomemetics" (ABiP) which may also be useful as an alternative to antibodies.

[0081] In addition to non-immunoglobulin protein frameworks, antibody properties have also been mimicked in compounds comprising RNA molecules and unnatural oligomers (e.g., protease inhibitors, benzodiazepines, purine derivatives and beta-turn mimics). Alternatively, known binding interactions between, for example, streptavidin and biotin, can be used to bind the gliadin fusion protein to the solid support.

[0082] Additional methods for linking the gliadin fusion protein to the solid support include the use of homobifunctional and heterobifunctional linkers. Zero-length cross linking reagents induce the direct conjugation of two ligands without the introduction of any extrinsic material. Agents that catalyze the formation of disulfide bonds belong in this category. Another example is reagents that induce the condensation of carboxy and primary amino groups to form an amide bond, such as carbodiimides, ethylchloroformate, Woodward's reagent K1, carbonyldiimidazole, etc. Homobifunctional reagents carry two identical functional groups, whereas heterobifunctional reagents contain two dissimilar functional groups. A vast majority of the heterobifunctional cross-linking agents contains a primary amine-reactive group and a thiol-reactive group. A novel heterobifunctional linker for formyl to thiol coupling was disclosed by Heindel, N. D. et al., Bioconjugate Chem. 2, 427-430 (1991). In a preferred embodiment, the covalent cross-linking agents are selected from reagents capable of forming disulfide (-S-S-), glycol (-CH(OH)-CH(OH)-), azo (-N=N-), sulfone (-S(=O)₂-), or ester (-C(=O)-O-) bridges.

[0083] Carboxylic acid groups residing on the surface of paramagnetic latex beads, internally dyed with Luminex dyes, can be converted to N-hydroxysuccinimide esters through the action of N-cyclohexyl-N'-(2-morpholinoethyl)carbodiimide metho-p-toluenesulfonate (CMC) and N-hydroxysuccinimide (NHS). After magnetic separation and washing, a mixture of the gliadin fusion protein and tTG is added in a detergent and buffered saline containing 10mM CaCl₂ at pH 7.4. The suspension is incubated for 1 hour with shaking at room temperature. After washing, the beads are blocked to reduce non-specific binding and then stored in particle diluent.

III. Method for Diagnosing a Subject with Celiac Disease

[0084] In some embodiments, the present invention provides a method for diagnosing a subject with celiac disease. The method includes contacting a sample of bodily fluid from the subject with an antigen of the present invention, including a recombinant deamidated gliadin including a hexamer having the sequence of SEQ ID NO:3. The method also includes detecting any antibody that has become specifically bound to the antigen, thus indicating the presence of celiac disease in the subject.

[0085] The sample of the present invention can be any bodily fluid. In some embodiments, the sample can be aqueous humor, bile, blood and blood plasma, breast milk, interstitial fluid, lymph, mucus, pleural fluid, pus, saliva, serum, sweat, tears, urine, cerebrospinal fluid, synovial fluid or intracellular fluid. In some embodiments, the sample is a blood sample.

[0086] The subject of the present invention can be any mammal. In some embodiments, the subject can be primates (e.g., humans), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice and the like. In other embodiments, the subject is a human.

[0087] The presence of the antibody bound to the solid support immobilized gliadin fusion protein or tTG-gliadin fusion protein complex can be detected by any means known in the art. In some embodiments, the detecting step can be performed using an assay such as ELISA, a RIA or an immunofluorescence assay. In other embodiments, the detecting step can be performed using an enzymatic method. Immunoassays which can be used in the detecting step include, for example, competitive and non-competitive assay systems such as Western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays, complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, protein A immunoassays, and the like. See, e.g., Harlow and Lane, *Using Antibodies, A Laboratory Manual*, Cold Spring Harbor Laboratory, New York (1999).

[0088] The antibody specific for the antigen can be any suitable antibody. In some embodiments, the antibody can be IgA, IgD, IgE, IgG or IgM. In other embodiments, the antibody can be IgG or IgA. One of skill in the art will appreciate that other antibodies are useful in the present invention.

IV. Kits

[0089] In some embodiments, the present invention provides a kit including an antigen as described above, wherein the recombinant deamidated gliadin includes a hexamer that is substantially identical to the sequence of SEQ ID NO:3 or having the sequence of SEQ ID NO:3, a detection reagent, and optionally at least one of buffers, salts, stabilizers and instructions.

[0090] Buffers, salts and stabilizers useful in the present invention include those known to one of skill, and can be found in Gennaro, Ed., *Remington's Pharmaceutical Sciences*, 18th Edition, Mack Publishing Co. (Easton, Pa.) 1990.

V. Examples

Example 1. Purification of D2-Hexamer with His Tag

[0091] The D2-hexamer with His tag can be purified using either native or denaturing conditions. In this example, the D2-hexamer was purified in the denaturing condition with 8M urea. A "classic" D2 hexamer with His tag was made in which the protein had the sequence of SEQ ID NO:7. Additionally, a "lysine-containing" D2 hexamer with His tag was made in which the protein had the sequence of SEQ ID NO:8.

[0092] Purification of the classic recombinant hexamer. The lysed cells from the 6 liter *E. coli* culture over-expressing the hexamer were suspended in the Equilibration Buffer (100 mM NaH₂PO₄, 8M Urea, 500 mM NaCl, 10 mM Imidazole, pH 8.0) at about 5ml/g wet weight. After stirring for 30 min at room temperature, the cellular debris were removed by centrifugation. The about 200 ml supernatant was added to 25ml of Ni-NTA resin pre-washed with the Equilibration Buffer, and mixed for 60 minutes at room temperature. The hexamer proteins bound to the resin were separated from the unbound lysate before being washed four times with 100 ml Washing Buffer (100 mM NaH₂PO₄, 8M urea, 500 mM NaCl, 20 mM imidazole, 0.5% Triton X100, pH 8.0). After the washing buffer was removed from the resin, the bound hexamer proteins were eluted with four volumes of 20ml Elution Buffer (100 mM NaH₂PO₄, 8M urea, 200 mM NaCl, 250 mM imidazole, pH 7.5). The eluted protein fractions were pooled, concentrated, and dialysed against 10mM MOPS, 150mM NaCl (pH7.4). Any precipitations observed were removed by centrifugation at 15k x g. The affinity purified proteins can be further purified with a size-exclusion column with 10mM MOPS, 150mM NaCl (pH7.4), monitored with UV at 230 nm. The fractions containing the first main peak were pooled and concentrated.

[0093] The purification method of the lysine-containing D2-hexamer recombinant protein was identical to that of the classic recombinant hexamer.

[0094] Characterization of the purified classic or lysine-containing hexamer proteins. The affinity purified protein

EP 2 788 760 B1

was analyzed by SDS-PAGE gel electrophoresis (Figure 1). The D2-hexamers that were further purified on the size-exclusion column as described above were analyzed by SDS-PAGE (Figure 1). Unexpectedly, both hexamers (classic and the lysine-containing) showed a major band around 45kd, corresponding to the size of a trimer of hexamer proteins. This aggregation of the hexamers is so strong that it is not dissociated under the denaturing conditions used in SDS-PAGE. Additionally, both hexamer proteins migrated at the position of about 45kd in a size-exclusion chromatogram. Without being bound to a particular theory, the surprising tendency of the hexamers to aggregate to form a trimer of hexamers may contribute to the improved immunoreactivity of the D2 hexamer.

Example 2. Preparation of Recombinant Deamidated Gliadin Antigen

[0095] This example provides a protocol that was used for the preparation of the "classic" His-tagged recombinant deamidated gliadin protein (SEQ ID NO:7).

Immobilization of the Recombinant Deamidated Gliadin Peptide (DGP) Antigen on Magnetic Beads

[0096] 10 mg of carboxyl modified magnetic beads are placed in a microfuge tube. 1000 μ L of 50 mM 2-(N-morpholino) ethanesulfonic acid (MES) pH 6.1 in 70% ethanol (EtOH) is added to the tube. The tube is vortexed and beads are magnetically separated. The supernatant is pipetted off and discarded. This wash process is repeated one more time.

[0097] 500 μ L of 120mM N-hydroxysuccinimide (NHS) in 50mM MES, pH 6.1 in 70% EtOH is added into the tube with beads and mixed. 500 μ L of N-Cyclohexyl-N'-(2-morpholinoethyl) carbodiimide metho-p-toluenesulfonate (CMC) in 50mM MES, pH 6.1 in 70% EtOH is added into the same tube with beads and mixed. The tube is incubated at room temperature for 30 minutes while mixing continuously.

[0098] The beads are separated from the supernatant and 1000 μ L of 5mM MES pH 6.1 in 10% EtOH is added. The beads are mixed, magnetically separated and the supernatant pipetted off and discarded. This wash process is repeated one more time.

[0099] The washed beads are suspended by adding 250 μ L of 5mM MES pH 6.1 and mixed. The recombinant DGP antigen (prepared as detailed earlier) is mixed in the bead coupling buffer (buffered saline containing detergents) to obtain a coating concentration of 5 μ g/mg that is added to the beads. This mixture is incubated at room temperature for 60 minutes with continuous mixing.

[0100] 1000 μ L of post coating wash buffer (buffered saline containing detergents, calcium chloride and preservatives) is added to the tube and mixed. The beads are magnetically separated and the supernatant pipetted off and discarded. This wash process is repeated 3 more times.

Bead blocking

[0101] 1000 μ L of blocking buffer (buffered saline containing detergents, calcium chloride, preservatives and blockers) added to the tube. The tube is incubated at 2-8° C with mixing. The beads are magnetically separated and the supernatant pipetted off and discarded at the end of incubation.

[0102] The beads are washed with Particle diluent (buffered saline containing detergents, calcium chloride, preservatives and blockers) by adding 1000 μ L of Particle diluent to the tube. The tube is mixed and the beads are magnetically separated and the supernatant pipetted off and discarded. This wash process is repeated 3 more times.

[0103] Add 1000 μ L of Particle diluent (100 μ L/mg particles) into the tube and store at 2-8° C in this buffer.

Example 3. Detection of Celiac Disease Using the Recombinant DGP Antigen

[0104] This example provides a method that was used for the detection of celiac disease using the classic His-tagged recombinant deamidated gliadin protein (SEQ ID NO:7) as an antigen.

Summary of the Celiac IgA and IgG immunoassay protocol:

[0105] The instrument, BioPlex 2200 (manufactured by Bio-Rad Laboratories) aspirates 5 μ L of sample from sample tube and dispenses it into a reaction vessel (RV) chased by 45 μ L of Wash buffer (phosphate buffered saline containing detergent and preservatives).

[0106] 100 μ L of Sample diluent (buffered saline containing detergent, preservatives and blockers) is added to the RV followed by 150 μ L of Wash buffer.

[0107] The RV is incubated for 130 seconds at 37° C.

[0108] 100 μ L of Particle reagent (a solution of recombinant deamidated gliadin coated beads in particle diluent) is added to the RV. The final sample dilution is 1/80.

EP 2 788 760 B1

[0109] The mixture is incubated for 1180 seconds at 37° C with intermittent mixing.

[0110] The beads are washed 3 times with 600 µL, then 300 µL, then 600 µL of Wash buffer with magnetic separation after each wash.

5 [0111] 50 µL of Conjugate Reagent (a mixture of anti-human IgA/IgG-phycoerythrin in conjugate diluent (buffered saline containing detergent, preservatives and blockers)) is added to the RV.

[0112] The mixture is incubated for 600 seconds at 37° C with intermittent mixing.

[0113] The beads are washed 3 times with 600 µL, then 300 µL, then 600 µL of Wash buffer with magnetic separation after each wash.

[0114] 50 µL of Wash buffer is added to the RV to re-suspend the beads.

10 [0115] The bead suspension is aspirated into the Luminex Detector module (LDM) and the median fluorescence of particles in each of the specified bead region is measured. Figure 2 shows the coating titration of the DGP classic hexamer.

Sensitivity in Celiac Tasting

15 [0116] Table 1 shows the amount of signal (relative fluorescence intensity, RFI) detected for normal and Celiac positive samples at different concentrations of DGP hexamer.

Table 1. RFI and Coating Concentration of DGP for "classic" DGP

Coating Concentration of DGP, µg/mg	RFI of Normal healthy sample		RFI of Celiac positive sample at cutoff	
	IgA	IgG	IgA	IgG
0.0	21	14	20	15
2.0	46	71	750	1152
5.0	47	76	808	1235
10.0	49	81	831	1262
25.0	51	81	844	1273
40.0	50	80	842	1275

Analysis of Celiac Samples

35 [0117] The following concordance study was comprised of 62 Celiac samples. Table 2 shows the results of the comparison of DGP hexamer and the predicate method.

Table 2. Concordance study of 62 Celiac samples using "classic" DGP

Analyte	Agreement with Predicate Method (INOVA)		
	Positive agreement	Negative agreement	Total agreement
IgA	97%	91%	95%
IgG	100%	94%	97%

45 [0118] Relative fluorescence intensity (RFI) was measured for normal and Celiac patient samples using a DGP hexamer (Table 3). Patient immunoreactivity was assessed by antibody index (AI) in which positive reactivity is >1.0.

Table 3. RFI and AI data for Normal and Celiac Patient samples using "classic" DGP

Sample	IgA	
	RFI	AI
2320644	170	0.2
2324881	49	0.0
GA61882J	956.0	2.1
GA61882R	903.0	1.5

EP 2 788 760 B1

(continued)

IgA		
Sample	RFI	AI
GA64089B	809.0	1.6
GA64089G	1111.0	2.3
GA640890	1753.5	3.6
A-9355	42.0	0.0
15902.0	2030	4.5
16313	14928.0	20.1
13424	5724.0	8.1
13425	5816.0	8.2
IgG		
Sample	RFI	AI
2320644	37.0	0
2324881	75.0	0
GG61791 B	1287.0	1.2
GG61791J	1319.0	1.3
GG66322P	204.0	0.2
GG66322R	3764.0	3.7
GG66322T	4847.0	4.2
A-9355	105.0	0.1
15902	5360.0	4.5
16313	10454.0	8.5
13424	4436.0	3.3
13425	2171.5	1.9

Example 4. Detection of Celiac disease using the recombinant DGP antigen with an additional lysine

[0119] In this example, the "lysine-containing" D2 hexamer protein (a His-tagged Recombinant Deamidated Gliadin Peptide with a lysine substituted for a glutamic acid residue at position 14 near the N-terminal region) (SEQ ID NO:8) was tested for sensitivity to Celiac disease.

[0120] The immobilization of this antigen on magnetic beads was done in the same manner as described in Example 2. Figure 3 shows the coating titration of the lysine-containing DGP hexamer.

[0121] The detection of Celiac disease using this antigen by immunoassay was performed in the same manner as described for the "classic" hexamer protein in Example 3.

Sensitivity in Celiac Testing

[0122] Table 4 shows the RFI for normal and Celiac positive samples at different concentrations of DGP hexamer.

Table 4. RFI and Coating Concentration of DGP for "lysine-containing" DGP

Coating Concentration of DGP, µg/mg	RFI of Normal healthy sample		RFI of a Celiac positive sample at cutoff	
	IgA	IgG	IgA	IgG
0.0	21	22	25	27

EP 2 788 760 B1

(continued)

Coating Concentration of DGP, µg/mg	RFI of Normal healthy sample		RFI of a Celiac positive sample at cutoff	
	IgA	IgG	IgA	IgG
0.5	45	60	623	1003
2.0	49	61	762	1170
5.0	61	89	814	1279
15.0	65	98	850	1336
45.0	64	95	875	1355

15 Analysis of Celiac Samples

[0123] Table 5 shows the relative fluorescence intensity (RFI) for normal and Celiac patient samples as measured by a DGP hexamer. Patient immunoreactivity was assessed by antibody index (AI) in which positive reactivity is >1.0.

20 **Table 5. RFI and AI data for Normal and Celiac Patient samples using "lysine-containing" DGP**

IgA		
Sample	RFI	AI
2320644	165	0.2
2324881	55	0
GA61882J	942.0	2.1
GA61882R	814.0	1.5
GA64089B	749.5	1.6
GA64089G	1042.0	2.2
GA64089O	1647.0	3.5
A-9355	45.0	0
15902.0	1920	4.5
16313	15549.0	23
13424	5407.0	8.2
13425	5587.5	8.4
IgG		
Sample	RFI	AI
2320644	47.0	0
2324881	70.0	0
GG61791 B	1216.5	1.2
GG61791J	1120.0	1.1
GG66322P	194.0	0.2
GG66322R	3476.0	3.6
GG66322T	4607.0	4.2
A-9355	153.5	0.1
15902	5541.0	4.6
16313	10723	8.7

EP 2 788 760 B1

(continued)

IgG		
Sample	RFI	AI
13424	3993.0	3.2
13425	1990.0	1.8

Example 5. Comparison Studies of DGP Trimer v. DGP Hexamer

[0124] The following concordance study consisting of 62 Celiac samples compared the predictive value of the DGP hexamer to a previously described gliadin antigen, a D2 trimer recombinant fusion protein (described previously in US 2009/0311727). The DGP hexamer showed improved positive agreement and total agreement versus DGP trimer (Table 6). These results demonstrate the improved sensitivity of the DGP hexamer as compared to the DGP trimer.

Table 6. Comparison concordance study

Analyte	Agreement with Predicate Method (INOVA)		
	Positive agreement	Negative agreement	Total agreement
IgG-DGP Trimer	84%	94%	89%
IgG-DGP Hexamer	100%	94%	97%

[0125] The DGP hexamer also showed surprisingly improved specificity as compared to the DGP trimer, which yielded many false positive results. This problem was eliminated by using the DGP hexamer.

[0126] Table 7 below shows data from a screen of 407 normal samples. DGP trimer gave 25% false positives whereas DGP hexamer gave only 0.5% false positives. The specificity for false positive detection is $\leq 1\%$.

Table 7. Screen of normal samples

	DGP Trimer	DGP Hexamer
Total Samples	407	407
False Positives	102	2

[0127] Figures 4a and 4b show the improved performance of the DGP hexamer as compared to the DGP trimer. In these studies, the bead coating concentration of the DGP hexamer was 5 times less than that of the DGP trimer, while the cutoff RFI signal was the same. The recombinant DGP hexamer had improved sensitivity as compared to the recombinant DGP trimer in both IgA (Figure 4a) and IgG (Figure 4b) assays.

SEQUENCE LISTING

[0128]

<110> Walker, Roger
Lu, Yabin
Desai, Urvee
Shan, Daming

<120> Recombinant Deaminated Gliadin Antigen

<130> 71401-858731

<140> US Not yet assigned

<141> Not yet assigned

<150> US 61/567,060

EP 2 788 760 B1

<151> 2011-12-05

<160> 15

5 <170> FastSEQ for Windows Version 4.0

<210> 1

<211> 16

<212> PRT

10 <213> Artificial Sequence

<220>

<223> synthetic gliadin protein D2 peptide

15 <400> 1

Gln Pro Glu Gln Pro Gln Gln Ser Phe Pro Glu Gln Glu Arg Pro Phe
1 5 10 15

20 <210> 2

<211> 5

<212> PRT

<213> Artificial Sequence

25 <220>

<223> synthetic peptide spacer, glycine-serine polymer spacer, flexible linker

<400> 2

30 Gly Gly Gly Gly Ser
1 5

<210> 3

<211> 121

35 <212> PRT

<213> Artificial Sequence

<220>

<223> synthetic recombinant gliadin protein D2 hexamer

40 <400> 3

Gln Pro Glu Gln Pro Gln Gln Ser Phe Pro Glu Gln Glu Arg Pro Phe
1 5 10 15
45 Gly Gly Gly Gly Ser Gln Pro Glu Gln Pro Gln Gln Ser Phe Pro Glu
20 25 30
Gln Glu Arg Pro Phe Gly Gly Gly Gly Ser Gln Pro Glu Gln Pro Gln

50

55

EP 2 788 760 B1

5 35 40 45
 Gln Ser Phe Pro Glu Gln Glu Arg Pro Phe Gly Gly Gly Gly Ser Gln
 50 55 60
 65 Pro Glu Gln Pro Gln Gln Ser Phe Pro Glu Gln Glu Arg Pro Phe Gly
 65 70 75 80
 Gly Gly Gly Ser Gln Pro Glu Gln Pro Gln Gln Ser Phe Pro Glu Gln
 85 90 95
 10 Glu Arg Pro Phe Gly Gly Gly Gly Ser Gln Pro Glu Gln Pro Gln Gln
 100 105 110
 115 Ser Phe Pro Glu Gln Glu Arg Pro Phe
 115 120

15 <210> 4
 <211> 6
 <212> PRT
 <213> Artificial Sequence

20 <220>
 <223> synthetic His-tag
 <400> 4

25 His His His His His His
 1 5

30 <210> 5
 <211> 15
 <212> PRT
 <213> Artificial Sequence

35 <220>
 <223> synthetic His-tag
 <400> 5

40 Met Arg Gly Ser His His His His His His Gly Ser Pro Glu Phe
 1 5 10 15

45 <210> 6
 <211> 15
 <212> PRT
 <213> Artificial Sequence

50 <220>
 <223> synthetic His-tag
 <400> 6

55 Met Arg Gly Ser His His His His His His Gly Ser Pro Lys Phe
 1 5 10 15

60 <210> 7
 <211> 136
 <212> PRT
 <213> Artificial Sequence

65 <220>
 <223> synthetic "classic" D2 hexamer with His tag, classic His-tagged recombinant deaminated gliadin protein (DGP)

EP 2 788 760 B1

<400> 7

5 Met Arg Gly Ser His His His His His His Gly Ser Pro Glu Phe Gln
 1 5 10 15
 Pro Glu Gln Pro Gln Gln Ser Phe Pro Glu Gln Glu Arg Pro Phe Gly
 20 25 30
 10 Gly Gly Gly Ser Gln Pro Glu Gln Pro Gln Gln Ser Phe Pro Glu Gln
 35 40 45
 Glu Arg Pro Phe Gly Gly Gly Gly Ser Gln Pro Glu Gln Pro Gln Gln
 50 55 60
 Ser Phe Pro Glu Gln Glu Arg Pro Phe Gly Gly Gly Gly Ser Gln Pro
 65 70 75 80
 15 Glu Gln Pro Gln Gln Ser Phe Pro Glu Gln Glu Arg Pro Phe Gly Gly
 85 90 95
 Gly Gly Ser Gln Pro Glu Gln Pro Gln Gln Ser Phe Pro Glu Gln Glu
 100 105 110
 Arg Pro Phe Gly Gly Gly Gly Ser Gln Pro Glu Gln Pro Gln Gln Ser
 115 120 125
 20 Phe Pro Glu Gln Glu Arg Pro Phe
 130 135

<210> 8

25 <211> 136

<212> PRT

<213> Artificial Sequence

<220>

30 <223> synthetic "lysine-containing" D2 hexamer with His tag, His-tagged recombinant deaminated gliadin protein with lysine substituted at position 14

<400> 8

35 Met Arg Gly Ser His His His His His His Gly Ser Pro Lys Phe Gln
 1 5 10 15
 Pro Glu Gln Pro Gln Gln Ser Phe Pro Glu Gln Glu Arg Pro Phe Gly
 20 25 30
 40 Gly Gly Gly Ser Gln Pro Glu Gln Pro Gln Gln Ser Phe Pro Glu Gln
 35 40 45
 Glu Arg Pro Phe Gly Gly Gly Gly Ser Gln Pro Glu Gln Pro Gln Gln
 50 55 60
 Ser Phe Pro Glu Gln Glu Arg Pro Phe Gly Gly Gly Gly Ser Gln Pro
 65 70 75 80
 45 Glu Gln Pro Gln Gln Ser Phe Pro Glu Gln Glu Arg Pro Phe Gly Gly
 85 90 95
 Gly Gly Ser Gln Pro Glu Gln Pro Gln Gln Ser Phe Pro Glu Gln Glu
 100 105 110
 Arg Pro Phe Gly Gly Gly Gly Ser Gln Pro Glu Gln Pro Gln Gln Ser
 115 120 125
 50 Phe Pro Glu Gln Glu Arg Pro Phe
 130 135

<210> 9

55 <211> 366

<212> DNA

<213> Artificial Sequence

<220>

EP 2 788 760 B1

<223> synthetic recombinant gliadin protein D2 hexamer

<400> 9

```

5      cagcccgaac aaccgcaaca atcattcccc gagcaagaaa ggccggttcgg tggcgggtggc 60
      tcgcagcccc aacaaccgca acaatcattc cccgagcaag aaaggccggt cgggtggcgggt 120
      ggctcgcagc ccgaacaacc gcaacaatca ttccccgagc aagaaaggcc ggggtggcgggt 180
      ggctcggaat tccagcccga acaaccgcaa caatcattcc ccgagcaaga aaggccggttc 240

10     ggtggcgggtg gctcgcagcc cgaacaaccg caacaatcat tccccgagca agaaaggccg 300
      ttcgggtggcg gtggctcgca gcccgaacaa ccgcaacaat cattccccga gcaagaaagg 360
      ccgttc                                           366
  
```

15 <210> 10
 <211> 224
 <212> PRT
 <213> Artificial Sequence

20 <220>
 <223> synthetic glutathione S-transferase (GST) protein

<400> 10

```

25     Met Ser Pro Ile Leu Gly Tyr Trp Lys Ile Lys Gly Leu Val Gln Pro
      1           5           10           15
      Thr Arg Leu Leu Leu Glu Tyr Leu Glu Glu Lys Tyr Glu Glu His Leu
      20
      Tyr Glu Arg Asp Glu Gly Asp Lys Trp Arg Asn Lys Lys Phe Glu Leu
      30     35           40           45
      Gly Leu Glu Phe Pro Asn Leu Pro Tyr Tyr Ile Asp Gly Asp Val Lys
      50           55           60
      Leu Thr Gln Ser Met Ala Ile Ile Arg Tyr Ile Ala Asp Lys His Asn
      65           70           75           80
      Met Leu Gly Gly Cys Pro Lys Glu Arg Ala Glu Ile Ser Met Leu Glu
      35     85           90           95
      Gly Ala Val Leu Asp Ile Arg Tyr Gly Val Ser Arg Ile Ala Tyr Ser
      100           105           110
      Lys Asp Phe Glu Thr Leu Lys Val Asp Phe Leu Ser Lys Leu Pro Glu
      40     115           120           125
      Met Leu Lys Met Phe Glu Asp Arg Leu Cys His Lys Thr Tyr Leu Asn
      130           135           140
      Gly Asp His Val Thr His Pro Asp Phe Met Leu Tyr Asp Ala Leu Asp
      45     145           150           155           160
      Val Val Leu Tyr Met Asp Pro Met Cys Leu Asp Ala Phe Pro Lys Leu
      165           170           175
      Val Cys Phe Lys Lys Arg Ile Glu Ala Ile Pro Gln Ile Asp Lys Tyr
      180           185           190
      Leu Lys Ser Ser Lys Tyr Ile Ala Trp Pro Leu Gln Gly Trp Gln Ala
      195           200           205
      Thr Phe Gly Gly Gly Asp His Pro Pro Lys Ser Asp Leu Val Pro Arg
      50     210           215           220
  
```

55 <210> 11
 <211> 282
 <212> PRT
 <213> Artificial Sequence

<220>

EP 2 788 760 B1

<223> synthetic gliadin fusion protein including GST and recombinant deaminated gliadin D2 hexamer

<400> 11

5 Met Ser Pro Ile Leu Gly Tyr Trp Lys Ile Lys Gly Leu Val Gln Pro
 1 5 10
 Thr Arg Leu Leu Leu Glu Tyr Leu Glu Glu Lys Tyr Glu Glu His Leu
 20 25 30
 Tyr Glu Arg Asp Glu Gly Asp Lys Trp Arg Asn Lys Lys Phe Glu Leu
 10 35 40 45
 Gly Leu Glu Phe Pro Asn Leu Pro Tyr Tyr Ile Asp Gly Asp Val Lys
 50 55 60
 Leu Thr Gln Ser Met Ala Ile Ile Arg Tyr Ile Ala Asp Lys His Asn
 65 70 75 80
 15
 Met Leu Gly Gly Cys Pro Lys Glu Arg Ala Glu Ile Ser Met Leu Glu
 85 90 95
 Gly Ala Val Leu Asp Ile Arg Tyr Gly Val Ser Arg Ile Ala Tyr Ser
 100 105 110
 20 Lys Asp Phe Glu Thr Leu Lys Val Asp Phe Leu Ser Lys Leu Pro Glu
 115 120 125
 Met Leu Lys Met Phe Glu Asp Arg Leu Cys His Lys Thr Tyr Leu Asn
 130 135 140
 25 Gly Asp His Val Thr His Pro Asp Phe Met Leu Tyr Asp Ala Leu Asp
 145 150 155 160
 Val Val Leu Tyr Met Asp Pro Met Cys Leu Asp Ala Phe Pro Lys Leu
 165 170 175
 Val Cys Phe Lys Lys Arg Ile Glu Ala Ile Pro Gln Ile Asp Lys Tyr
 180 185 190
 30 Leu Lys Ser Ser Lys Tyr Ile Ala Trp Pro Leu Gln Gly Trp Gln Ala
 195 200 205
 Thr Phe Gly Gly Gly Asp His Pro Pro Lys Ser Asp Leu Val Pro Arg
 210 215 220
 Gln Pro Glu Gln Pro Gln Gln Ser Phe Pro Glu Gln Glu Arg Pro Phe
 225 230 235 240
 35 Gly Gly Gly Gly Ser Gln Pro Glu Gln Pro Gln Gln Ser Phe Pro Glu
 245 250 255
 Gln Glu Arg Pro Phe Gly Gly Gly Gly Ser Gln Pro Glu Gln Pro Gln
 260 265 270
 40 Gln Ser Phe Pro Glu Gln Glu Arg Pro Phe
 275 280

<210> 12

<211> 16

<212> PRT

45 <213> Artificial Sequence

<220>

<223> synthetic variants of gliadin protein D2 peptide

50 <220>

<221> VARIANT

<222> (1)...(13)

<223> at least one Glx is Gln and at least one Glx is Glu

55 <400> 12

Glx Pro Glx Glx Pro Glx Glx Ser Phe Pro Glx Glx Glx Arg Pro Phe
 1 5 10 15

EP 2 788 760 B1

<210> 13
<211> 5
<212> PRT
<213> Artificial Sequence

5

<220>
<223> synthetic peptide spacer, glycine-serine polymer spacer, flexible linker, repeated an undefined number of times, (GGGS)n

10

<400> 13

Gly Gly Gly Gly Ser
1 5

15

<210> 14
<211> 5
<212> PRT
<213> Artificial Sequence

20

<220>
<223> synthetic peptide spacer, glycine-serine polymer spacer, flexible linker, repeated an undefined number of times, (GSGGS)n

25

<400> 14

Gly Ser Gly Gly Ser
1 5

30

<210> 15
<211> 4
<212> PRT
<213> Artificial Sequence

35

<220>
<223> synthetic peptide spacer, glycine-serine polymer spacer, flexible linker, repeated an undefined number of times, (GGGS)n

<400> 15

40

Gly Gly Gly Ser
1

Claims

45

1. An antigen for detecting celiac disease comprising a recombinant deamidated gliadin comprising a hexamer of peptides, wherein each peptide has the sequence of SEQ ID NO:1, wherein the recombinant deamidated gliadin is covalently linked to a tag to form a gliadin fusion protein, wherein the gliadin fusion protein is immobilized on a solid support, and wherein the recombinant deamidated gliadin is capable of binding to anti-deamidated gliadin antibodies.

50

2. The antigen of claim 1, wherein

(i) the hexamer comprises a spacer separating each peptide, preferably the spacer has the sequence of SEQ ID NO:2, or

55

(ii) the hexamer has the sequence of SEQ ID NO:3.

3. The antigen of claim 1, wherein the tag is selected from the group consisting of a Glutathione S-transferase (GST) and a His-tag.

4. The antigen of claim 3, wherein the His-tag has the sequence selected from the group consisting of SEQ ID NO:4, SEQ ID NO:5, and SEQ ID NO:6, preferably the recombinant deamidated gliadin has the sequence selected from the group consisting of SEQ ID NO:7 and SEQ ID NO:8.
- 5 5. The antigen of claim 3, wherein the tag is GST.
6. The antigen of claim 3, wherein the antigen further comprises tissue Transglutaminase (tTG) to form a tTG-gliadin fusion protein complex, preferably the tTG and the gliadin fusion protein are covalently linked by a cross-linker, most preferably the cross-linker is a member selected from the group consisting of a heterobifunctional crosslinker and a homobifunctional crosslinker.
- 10 7. The antigen of claim 6, wherein the cross-linker is a homobifunctional crosslinker, preferably the cross-linker is a member selected from the group consisting of bis(sulfosuccinimidyl)suberate (BS3), ethylene glycol bis[succinimidylsuccinate] (EGS), ethylene glycol bis[sulfosuccinimidylsuccinate] (sulfo-EGS), bis[2-(succinimidooxycarbonyloxy)ethyl]sulfone (BSOCOES), dithiobis(succinimidyl)propionate (DSP), 3,3'-dithiobis(sulfosuccinimidylpropionate) (DTSSP), disuccinimidyl suberate (DSS), disuccinimidyl glutarate (DSG), methyl N-succinimidyl adipate (MSA), disuccinimidyl tartarate (DST), 1,5-difluoro-2,4-dinitrobenzene (DFDNB), 1-ethyl-3-[3-dimethylaminopropyl]-carbodiimide hydrochloride (EDC or EDAC), sulfosuccinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (sulfo-SMCC), N-hydroxysulfosuccinimide (sulfo-NHS), hydroxylamine and Sulfo-LC-SPDP (N-succinimidyl 3-(2-pyridyldithio)-propionate) and sulfosuccinimidyl 6-(3'-[2-pyridyldithio]-propionamido)-hexanoate (sulfo-LC-SPDP), most preferably the cross-linker is bis(sulfosuccinimidyl)suberate (BS3).
- 15 20 8. An antigen for detecting celiac disease prepared by the process comprising:
- 25 (a) contacting a solid support with a gliadin fusion protein, wherein the gliadin fusion protein comprises a recombinant deamidated gliadin comprising a hexamer of peptides each having the sequence of SEQ ID NO:1 and wherein the recombinant deamidated gliadin is covalently linked to a tag, such that the gliadin fusion protein is immobilized on the solid support, thereby preparing the antigen for detecting celiac disease.
- 30 9. The antigen of claim 8, wherein the recombinant deamidated gliadin
- (i) comprises the hexamer having the sequence of SEQ ID NO:3; or
- (ii) has the sequence selected from the group consisting of SEQ ID NO:7 and SEQ ID NO:8.
- 35 10. The antigen of claim 8, wherein the gliadin fusion protein is immobilized on the solid support via the tag.
11. The antigen of claim 8, wherein the process further comprises contacting the gliadin fusion protein with a tissue Transglutaminase (tTG) prior to contacting step (a) to form at least one covalent bond between the gliadin fusion protein and the tTG.
- 40 12. The antigen of claim 8, wherein the process further comprises
- (b) contacting the antigen with a cross-linker to cross-link the gliadin fusion protein to the tTG.
- 45 13. A method for diagnosing celiac disease in a subject, the method comprising:
- (a) contacting a sample of bodily fluid from the subject with an antigen of claim 1, comprising a recombinant deamidated gliadin comprising a hexamer having the sequence of SEQ ID NO:3; and
- (b) detecting any antibody that has become specifically bound to the antigen, thus indicating the presence of celiac disease in the subject.
- 50 14. The method of claim 13, wherein
- (i) the sample is a blood sample; or
- (ii) the detecting step is performed using an assay selected from the group consisting of ELISA, a RIA and an immunofluorescence assay; or
- (iii) the antibody specific for the antigen is selected from the group consisting of IgG and IgA.
- 55

15. A kit comprising:

an antigen of claim 1, comprising a recombinant deamidated gliadin comprising a hexamer having the sequence of SEQ ID NO:3;
 a detection reagent; and
 optionally at least one member selected from the group consisting of buffers, salts, stabilizers and instructions.

Patentansprüche

1. Antigen zum Nachweis von Zöliakie, umfassend ein rekombinantes deamidiertes Gliadin, das ein Hexamer von Peptiden umfasst, wobei jedes Peptid die Sequenz von SEQ ID Nr. 1 aufweist, wobei das rekombinante deamidierte Gliadin kovalent mit einem Protein-Tag verknüpft ist, wobei ein Gliadin-Fusionsprotein entsteht, wobei das Gliadin-Fusionsprotein auf einem festen Träger immobilisiert ist und wobei das rekombinante deamidierte Gliadin an Anti-deamidiertes-Gliadin-Antikörper binden kann.
2. Antigen gemäß Anspruch 1, wobei
 - (i) das Hexamer einen Spacer umfasst, der die Peptide jeweils voneinander trennt, wobei der Spacer vorzugsweise die Sequenz von SEQ ID Nr. 2 aufweist; oder
 - (ii) das Hexamer die Sequenz von SEQ ID Nr. 3 aufweist.
3. Antigen gemäß Anspruch 1, wobei das Protein-Tag aus der Gruppe ausgewählt ist, die aus einer Glutathion-S-Transferase (GST) und einem His-Tag besteht.
4. Antigen gemäß Anspruch 3, wobei das His-Tag eine Sequenz aufweist, die aus der Gruppe ausgewählt ist, die aus SEQ ID Nr. 4, SEQ ID Nr. 5 und SEQ ID Nr. 6 besteht, wobei das rekombinante deamidierte Gliadin vorzugsweise eine Sequenz aufweist, die aus der Gruppe ausgewählt ist, die aus SEQ ID Nr. 7 und SEQ ID Nr. 8 besteht.
5. Antigen gemäß Anspruch 3, wobei es sich bei dem Protein-Tag um GST handelt.
6. Antigen gemäß Anspruch 3, wobei das Antigen weiterhin Gewebe-Transglutaminase (tTG) umfasst, wobei ein tTG-Gliadin-Fusionsprotein-Komplex entsteht, wobei das tTG und das Gliadin-Fusionsprotein vorzugsweise durch einen Vernetzer kovalent miteinander verknüpft sind, wobei der Vernetzer am meisten bevorzugt ein Vertreter ist, der aus der Gruppe ausgewählt ist, die aus einem heterobifunktionellen Vernetzer und einem homobifunktionellen Vernetzer besteht.
7. Antigen gemäß Anspruch 6, wobei der Vernetzer ein homobifunktioneller Vernetzer ist, wobei der Vernetzer vorzugsweise ein Vertreter ist, der aus der Gruppe ausgewählt ist, die aus Bis(sulfosuccinimidyl)suberat (BS3), Ethylenglycolbis[succinimidylsuccinat] (EGS), Ethylenglycolbis[sulfosuccinimidylsuccinat] (Sulfo-EGS), Bis[2-(succinimidooxycarbonyloxy)ethyl]sulfon (BSOCOES), Dithiobis(succinimidyl)propionat (DSP), 3,3'-Dithio-bis(sulfosuccinimidylpropionat) (DTSSP), Disuccinimidylsuberat (DSS), Disuccinimidylglutarat (DSG), Methyl-N-succinimidyladipat (MSA), Disuccinimidyltartrat (DST), 1,5-Difluor-2,4-dinitrobenzol (DFDNB), 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimid-Hydrochlorid (EDC oder EDAC), Sulfosuccinimidyl-4-(N-maleimidomethyl)cyclohexan-1-carboxylat (Sulfo-SMCC), N-Hydroxysulfosuccinimid (Sulfo-NHS), Hydroxylamin und Sulfo-LC-SPDP (N-Succinimidyl-3-(2-pyridyldithio)propionat) und Sulfosuccinimidyl-6-(3'-[2-pyridyldithio]propionamido)hexanoat (Sulfo-LC-SPDP) besteht, wobei es sich bei dem Vernetzer am meisten bevorzugt um Bis(sulfosuccinimidyl)suberat (BS3) handelt.
8. Antigen zum Nachweis von Zöliakie, hergestellt nach einem Verfahren, umfassend:
 - (a) In-Kontakt-Bringen eines festen Trägers mit einem Gliadin-Fusionsprotein, wobei das Gliadin-Fusionsprotein ein rekombinantes deamidiertes Gliadin, das ein Hexamer von Peptiden umfasst, die jeweils die Sequenz von SEQ ID Nr. 1 aufweisen, umfasst und wobei das rekombinante deamidierte Gliadin kovalent mit einem Protein-Tag verknüpft ist, so dass das Gliadin-Fusionsprotein auf dem festen Träger immobilisiert ist, wodurch das Antigen zum Nachweis von Zöliakie hergestellt wird.
9. Antigen gemäß Anspruch 8, wobei das rekombinante deamidierte Gliadin

EP 2 788 760 B1

- (i) das Hexamer mit der Sequenz von SEQ ID Nr. 3 umfasst; oder
- (ii) eine Sequenz aufweist, die aus der Gruppe ausgewählt ist, die aus SEQ ID Nr. 7 und SEQ ID Nr. 8 besteht.

5 10. Antigen gemäß Anspruch 8, wobei das Gliadin-Fusionsprotein über das Protein-Tag auf dem festen Träger immobilisiert ist.

10 11. Antigen gemäß Anspruch 8, wobei das Verfahren vor dem Schritt des In-Kontakt-Bringens (a) weiterhin das In-Kontakt-Bringen des Gliadin-Fusionsproteins mit einer Gewebe-Transglutaminase (tTG) umfasst, wobei wenigstens eine kovalente Bindung zwischen dem Gliadin-Fusionsprotein und der tTG entsteht.

12. Antigen gemäß Anspruch 8, wobei das Verfahren weiterhin umfasst:

15 (b) das In-Kontakt-Bringen des Antigens mit einem Vernetzer, um das Gliadin-Fusionsprotein mit der tTG zu vernetzen.

13. Verfahren zum Diagnostizieren von Zöliakie bei einem Probanden, wobei das Verfahren umfasst:

20 (a) das In-Kontakt-Bringen einer Probe einer Körperflüssigkeit von dem Probanden mit einem Antigen gemäß Anspruch 1, das ein rekombinantes deamidiertes Gliadin, das ein Hexamer mit der Sequenz von SEQ ID Nr. 3 umfasst, umfasst; und

(b) Nachweisen von Antikörper, der spezifisch an das Antigen gebunden wurde, was die Anwesenheit von Zöliakie bei dem Probanden anzeigt.

25 14. Verfahren gemäß Anspruch 13, wobei

(i) die Probe eine Blutprobe ist; oder

(ii) der Schritt des Nachweisens mit Hilfe eines Assays durchgeführt wird, das aus der Gruppe ausgewählt ist, die aus ELISA, einem RIA und einem Immunfluoreszenzassay besteht; oder

(iii) der für das Antigen spezifische Antikörper aus der Gruppe ausgewählt ist, die aus IgG und IgA besteht.

30 15. Kit, umfassend:

35 ein Antigen gemäß Anspruch 1, das ein rekombinantes deamidiertes Gliadin, das ein Hexamer mit der Sequenz von SEQ ID Nr. 3 umfasst, umfasst;

ein Nachweisreagens; und

gegebenenfalls wenigstens einen Vertreter, der aus der Gruppe ausgewählt ist, die aus Puffern, Salzen, Stabilisatoren und Anweisungen besteht.

40 **Revendications**

45 1. Antigène pour détecter la maladie coeliaque, qui comprend une gliadine désamidée recombinante comprenant un hexamère de peptides, dans lequel chaque peptide a la séquence du SEQ ID n° 1, dans lequel la gliadine désamidée recombinante est liée de façon covalente à un marqueur pour former une protéine de fusion de gliadine, dans lequel la protéine de fusion de gliadine est immobilisée sur un support solide, et dans lequel la gliadine désamidée recombinante est capable de se lier à des anticorps anti-gliadine désamidée.

2. Antigène selon la revendication 1, dans lequel

50 (i) l'hexamère comprend un espaceur séparant chaque peptide, et l'espaceur a de préférence la séquence du SEQ ID n° : 2, ou

(ii) l'hexamère a la séquence du SEQ ID n° : 3.

55 3. Antigène selon la revendication 1, dans lequel le marqueur est sélectionné dans le groupe composé de la glutathione-S-transférase (GST) et d'un His-marqueur.

4. Antigène selon la revendication 3, dans lequel le His-marqueur a la séquence sélectionnée dans le groupe composé du SEQ ID n° : 4, du SEQ ID n° : 5 et du SEQ ID n° : 6, et la gliadine désamidée recombinante a de préférence la

EP 2 788 760 B1

séquence sélectionnée dans le groupe composé du SEQ ID n° : 7 et du SEQ ID n° : 8.

5. Antigène selon la revendication 3, dans lequel le marqueur est GST.

6. Antigène selon la revendication 3, dans lequel l'antigène comprend en outre de la transglutaminase de tissu (tTG) pour former un complexe tTG-protéine de fusion de gliadine, et de préférence la tTG et la protéine de fusion de gliadine sont liées de façon covalente par un agent de réticulation, et de façon la plus préférentielle, l'agent de réticulation est un membre sélectionné dans le groupe composé d'un agent de réticulation hétérobifonctionnel et d'un agent de réticulation homobifonctionnel.

7. Antigène selon la revendication 6, dans lequel l'agent de réticulation est un agent de réticulation homobifonctionnel, et de préférence l'agent de réticulation est un membre sélectionné dans le groupe composé du subérate de bis(sulfosuccinimidyle) (BS3), du bis[succinimidylsuccinate] d'éthylène glycol (EGS), du bis[sulfosuccinimidylsuccinate] d'éthylène glycol (sulfo-EGS), de la bis[2-(succinimidooxycarbonyloxy)éthyl]sulfone (BSOCOES), du propionate de dithiobis(succinimidyle) (DSP), du 3,3'-dithiobis(sulfosuccinimidylpropionate) (DTSSP), du subérate de disuccinimidyle (DSS), du glutarate de disuccinimidyle (DSG), du méthyladipate de N-succinimidyle (MSA), du tartrate de disuccinimidyle (DST), du 1,5-difluoro-2,4-dinitrobenzène (DFDNB), du chlorhydrate de 1-éthyl-3-[3-diméthylaminopropyl]-carbodiimide (EDC ou EDAC), du sulfosuccinimidyl-4-(N-maléimidométhyl)cyclohexane-1-carboxylate (sulfo-SMCC), du N-hydroxysulfosuccinimide (sulfo-NHS), de l'hydroxylamine et du sulfo-LC-SPDP, du (3-(2-pyridyl-dithio)-propionate de N-succinimidyle) et du 6-(3'-[2-pyridylthio]-propionamido)-hexanoate de sulfosuccinimidyle (sulfo-LC-SPDP), et de façon la plus préférentielle, l'agent de réticulation est le subérate de bis(sulfosuccinimidyle) (BS3).

8. Antigène pour détecter la maladie coeliaque, préparé par le procédé consistant à :

(a) mettre un support solide en contact avec une protéine de fusion de gliadine, dans lequel la protéine de fusion de gliadine comprend une gliadine désamidée recombinante comprenant un hexamère de peptides, chacun ayant la séquence du SEQ ID n° 1 et dans lequel la gliadine désamidée recombinante est liée de façon covalente à un marqueur de façon telle que la protéine de fusion de gliadine est immobilisée sur le support solide, préparant ainsi l'antigène de détection de la maladie coeliaque.

9. Antigène selon la revendication 8, dans lequel la gliadine désamidée recombinante :

- (i) comprend l'hexamère ayant le SEQ ID n° 3 ; ou
- (ii) a la séquence sélectionnée dans le groupe composé du SEQ ID n° 7 et du SEQ ID n° 8.

10. Antigène selon la revendication 8, dans lequel la protéine de fusion de gliadine est immobilisée sur le support solide via le marqueur.

11. Antigène selon la revendication 8, dans lequel le processus comprend en outre la mise en contact de la protéine de fusion de gliadine avec une transglutaminase de tissu (tTG) avant l'étape de mise en contact (a) pour former au moins une liaison covalente entre la protéine de fusion de gliadine et la tTG.

12. Antigène selon la revendication 8, dans lequel le processus comprend en outre

(b) la mise en contact de l'antigène avec un agent de réticulation pour réticuler la protéine de fusion de gliadine à la tTG.

13. Procédé de diagnostic de la maladie coeliaque chez un sujet, le procédé comprenant les étapes consistant à :

(a) mettre en contact un échantillon de fluide corporel du sujet avec un antigène selon la revendication 1, comprenant une gliadine désamidée recombinante comprenant un hexamère ayant la séquence du SEQ ID n° 3 ; et

(b) détecter tout anticorps qui s'est spécifiquement lié à l'antigène, indiquant ainsi la présence d'une maladie coeliaque chez le sujet.

14. Procédé selon la revendication 13, dans lequel

EP 2 788 760 B1

- (i) l'échantillon est un échantillon sanguin ; ou
- (ii) l'étape de détection est réalisée en utilisant un dosage sélectionné dans le groupe composé d'un essai ELISA, d'un radioimmunoessai (RIA) et d'un essai d'immunofluorescence ; ou
- (iii) l'anticorps spécifique de l'antigène est sélectionné dans le groupe composé de l'IgG et de l'IgA.

5

15. Kit comprenant :

un antigène selon la revendication 1, comprenant une gliadine désamidée recombinante comprenant un hexamère ayant le SEQ ID n° 3 ;
un réactif de détection ; et
en option au moins un élément sélectionné dans le groupe composé de tampons, de sels, d'agents stabilisants et d'instructions.

10

15

20

25

30


35


40


45

50


55








A



B



REFERENCES CITED IN THE DESCRIPTION

This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description

- US 5260203 A, Ladner [0073]
- US 6818418 B [0075]
- US 7115396 B [0075]
- US 5770380 A, Hamilton [0079]
- US 20090311727 A [0124]
- US 61567060 B [0128]

Non-patent literature cited in the description

- **BRANDTZAEG, P.** *Mechanisms of gastrointestinal reactions to food. Environmental Toxicology and Pharmacology*, 1997, vol. 4, 9-24 [0001]
- **HOLMES GKT.** Malignancy in coeliac disease-effect of a gluten-free diet. *Gut*, 1989, vol. 30, 333-338 [0001]
- **FERGUSON A et al.** Definitions and diagnostic criteria of latent and potential coeliac disease. Epidemiology of CD. *Dyn Nutr Res*, Basel, Karger, 1992, vol. 2, 119-127 [0001]
- **SIRGUS N et al.** Prevalence of coeliac disease in diabetic children and adolescents in Sweden. *Acta Paediatr*, 1993, vol. 66, 491-494 [0001]
- **ZUBILLAGA P et al.** Down syndrome and coeliac disease. *J Pediatr Gastroenterol Nutr*, 1993, vol. 16, 168-171 [0001]
- Revised criteria for diagnosis of coeliac disease. **WALKER-SMITH et al.** Arch Dis Child. Report of Working group of European Society of Pediatric Gastroenterology and Nutrition, 1990, vol. 65, 909-911 [0003]
- Validation and standardization of serological screening tests for coeliac disease in 1996. **STERN M et al.** 3rd EMRC/ESPGAN Workshop. 1996, 9-24 [0004]
- **CATASSI C et al.** Quantitative antigliadin antibody measurement in clinical practice: an Italian multicenter study. *Ital J Gastroenterol Hepatol*, 1999, vol. 31, 366-370 [0004]
- **GARROTE J A ; SORELL L ; ALFONSO P et al.** A simple visual immunoassay for the screening of coeliac disease. *Eur. J Clin Invest*, 1999, vol. 29, 697-699 [0004]
- **DIETRICH W et al.** Identification of tissue transglutaminase as the auto antigen of celiac disease. *Nat Med.*, 1997, vol. 3, 797-801 [0005]
- **SULKANEN S et al.** Tissue transglutaminase autoantibody enzyme-linked immunosorbent assay in detecting celiac disease. *Gastroenterology*, 1998, vol. 115, 1322-1328 [0005]
- **SIESSLER J et al.** Antibodies to human recombinant tissue transglutaminase measured by radioligand assay: Evidence for high diagnostic sensitivity for celiac disease. *Horm Metab Res*, 1999, vol. 31, 375-379 [0005]
- **ALTSCHUL et al.** *Nuc. Acids Res.*, 1977, vol. 25, 3389-3402 [0028]
- **ALTSCHUL et al.** *J. Mol. Biol.*, 1990, vol. 215, 403-410 [0028]
- **HENIKOFF ; HENIKOFF.** *Proc. Natl. Acad. Sci. USA*, 1989, vol. 89, 10915 [0028]
- **KARLIN ; ALTSCHUL.** *Proc. Nat'l. Acad. Sci.*, 1993, vol. 90, 5873-5787 [0029]
- **ECKSTEIN.** *Oligonucleotides and Analogues: A Practical Approach.* Oxford University Press [0031]
- Using Antibodies. **HARLOW ; LANE.** *A Laboratory Manual.* 1998 [0033]
- **ALEANZI et al.** *Clin Chem*, 2001, vol. 47 (11), 2023 [0037]
- **SAMBROOK ; RUSSELL.** *Molecular Cloning, A Laboratory Manual.* 2001 [0057]
- **KRIEGLER.** *Gene Transfer and Expression: A Laboratory Manual.* 1990 [0057]
- *Current Protocols in Molecular Biology*, 1994 [0057]
- **BEAUCAGE ; CARUTHERS.** *Tetrahedron Letts.*, 1981, vol. 22 (20), 1859-1862 [0060]
- **NEEDHAM-VANDEVANTER et al.** *Nucleic Acids Res.*, 1984, vol. 12, 6159-6168 [0060]
- **PALVA et al.** *Gene*, 1983, vol. 22, 229-235 [0063]
- **MOSBACH et al.** *Nature*, 1983, vol. 302, 543-545 [0063]
- **R. SCOPES.** *Protein Purification.* Springer--Verlag, 1982 [0069]
- *Methods in Enzymology.* **DEUTSCHER.** *Guide to Protein Purification.* Academic Press, Inc, 1990, vol. 182 [0069]
- **KU et al.** *Proc. Natl. Acad. Sci. U.S.A.*, 1995, vol. 92 (14), 6552-6556 [0074]
- **BESTE et al.** *Proc. Natl. Acad. Sci. U.S.A.*, 1999, vol. 96 (5), 1898-1903 [0077]
- **MURALI et al.** *Cell Mol Biol*, 2003, vol. 49 (2), 209-216 [0080]

EP 2 788 760 B1

- **HEINDEL, N. D. et al.** *Bioconjugate Chem.*, 1991, vol. 2, 427-430 **[0082]**
- **HARLOW ; LANE.** *Using Antibodies, A Laboratory Manual.* Cold Spring Harbor Laboratory, 1999 **[0087]**
- *Remington's Pharmaceutical Sciences.* Mack Publishing Co, 1990 **[0090]**

专利名称(译)	重组脱酰胺醇麦醇溶蛋白抗原		
公开(公告)号	EP2788760B1	公开(公告)日	2017-02-15
申请号	EP2012855209	申请日	2012-12-03
[标]申请(专利权)人(译)	比奥-雷德实验室股份有限公司		
申请(专利权)人(译)	Bio-Rad实验室 , INC.		
当前申请(专利权)人(译)	Bio-Rad实验室 , INC.		
[标]发明人	WALKER ROGER LU YABIN DESAI URVEE SHAN DAMING		
发明人	WALKER, ROGER LU, YABIN DESAI, URVEE SHAN, DAMING		
IPC分类号	G01N33/53 C07K14/415 C12N15/62 C12N9/10 C12N15/54 G01N33/564 G01N33/68		
CPC分类号	C07K14/415 C07K2319/21 C07K2319/23 C12N9/1044 C12Y203/02013 G01N33/564 G01N2800/06 G01N33/531 G01N33/6893		
优先权	61/567060 2011-12-05 US		
其他公开文献	EP2788760A2 EP2788760A4		
外部链接	Espacenet		

摘要(译)

本发明提供了一种通过使来自受试者的体液样品与固定在固体支持物上的麦醇溶蛋白融合蛋白的六聚体形成的抗原接触来确定受试者是否患有乳糜泻的方法。抗原的麦醇溶蛋白融合蛋白包括与标签例如谷胱甘肽-S 转移酶 (GST) 蛋白连接的重组脱酰胺的麦醇溶蛋白。通过将麦醇溶蛋白融合蛋白固定在固体支持物上来制备抗原。抗原可以进一步包括与麦醇溶蛋白融合蛋白交联的组织转谷氨酰胺酶 (tTG) 。当存在tTG时, 将tTG和重组的脱酰胺的麦醇溶蛋白混合在一起, 然后固定至固相。

Table 1. RFI and Coating Concentration of DGP for "classic" DGP

Coating Concentration of DGP, µg/mg	RFI of Normal healthy sample		RFI of Celiac positive sample at cutoff	
	IgA	IgG	IgA	IgG
0.0	21	14	20	15
2.0	46	71	750	1152
5.0	47	76	808	1235
10.0	49	81	831	1262
25.0	51	81	844	1273
40.0	50	80	842	1275